Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2012
At a glance
- Drugs Erlotinib; Sunitinib
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History